STOCK TITAN

Amarin to Present at Jefferies London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Amarin Corporation (NASDAQ:AMRN) announced that CEO Karim Mikhail will participate in the Jefferies London Healthcare Conference from November 15-17, 2022. Mikhail's presentation is scheduled for November 16, 2022, at 9:40 a.m. ET (2:40 p.m. GMT+1).

This event will be webcast live, with an archived version available on Amarin's Investor Relations website. The company focuses on advancing cardiovascular disease management through scientific research and clinical trials.

Positive
  • None.
Negative
  • None.

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Jefferies London Healthcare Conference.

Jefferies London Healthcare Conference (November 15-17th, 2022; London)
  
Date/Time:November 16, 2022, 9:40 a.m. ET/ 2:40 p.m. GMT+1
  
Webcast:https://wsw.com/webcast/jeff255/amrn/1851714

The presentation will be webcast live and archived on the Company’s website in the Investor Relations section under Events and Presentations at  Events | Amarin Corporation plc.

About Amarin  

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.  

Availability of Other Information About Amarin

Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information  
Investor Inquiries:  
Investor Relations  
Amarin Corporation plc  
IR@amarincorp.com (investor inquiries) 

Media Inquiries:
Communications  
Amarin Corporation plc  
PR@amarincorp.com (media inquiries)  


FAQ

When is Amarin's presentation at the Jefferies London Healthcare Conference?

Amarin's presentation is scheduled for November 16, 2022, at 9:40 a.m. ET (2:40 p.m. GMT+1).

Who will represent Amarin at the Jefferies London Healthcare Conference?

Karim Mikhail, Amarin's president and CEO, will represent the company at the conference.

Where can I watch Amarin's presentation at the Jefferies London Healthcare Conference?

The presentation will be webcast live and archived on Amarin's Investor Relations website.

What is the focus of Amarin Corporation?

Amarin focuses on innovative solutions in cardiovascular disease management and scientific research.

What are the dates of the Jefferies London Healthcare Conference?

The Jefferies London Healthcare Conference is scheduled for November 15-17, 2022.

Amarin Corp Plc

NASDAQ:AMRN

AMRN Rankings

AMRN Latest News

AMRN Stock Data

187.86M
404.75M
1.6%
17.05%
4.36%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
DUBLIN 2